Author Claim Review

 Quick Explanation Copied

 Long Explanation

Scientific Profile and Metrics

OpenAlex records Efthimios Deligeoroglou (ORCID 0000-0002-7327-493X) with 108 works, 2,064 total citations, and an h-index of 28, classified mainly in Medicine, Internal medicine, Gynecology, Genetics, and Biology OpenAlex bibliometrics for the author. Citation density peaked 2009–2012 (211–345 citations/year), while 2023–2026 works show negligible citations, partly a lag effect and partly reduced output (1–5 works/year vs 5–8 in peak years) Year-by-year citation and work counts.

Signature Contributions

His most cited work is a randomized comparison in hydrosalpinx patients showing proximal tubal occlusion and salpingectomy produce similar IVF improvement (155 citations; Fertility and Sterility, 2006) Hydrosalpinx IVF surgery comparison. Other high-impact contributions: persistence of hyperandrogenism in postmenopausal PCOS (107 citations, JCEM 2010) PCOS hyperandrogenism after menopause; HPV immunology review (103 citations, 2013) HPV immunology review; adolescent amenorrhea evaluation (95 citations) Adolescent amenorrhea review; and the 111-patient Williams vaginoplasty/Creatsas modification neovagina series (81 citations) — a rare large surgical case series in MRKHS Neovagina surgical series (n=111). His 1997 single-author review of dysfunctional uterine bleeding notes ~95% of adolescent DUB stems from delayed hypothalamic-pituitary-ovarian maturation Adolescent DUB review (1997), and he has contributed psychosomatic data on anxiety/depression in adolescents with PCOS and MRKHS Adolescent PCOS/MRKHS psychosomatic study.

Critical Assessment

• Strengths: sustained, first-author leadership in pediatric/adolescent gynecology; publication in top-tier clinical journals (Fertility and Sterility, JCEM); rare large surgical series; consistent collaboration network (Creatsas, Mastorakos, Chrousos).
• Limitations: no primary institution listed in OpenAlex, weakening verification of current affiliation Missing affiliation metadata in OpenAlex; a probable second identity cluster (49 works, h-index 18 under a spelling variant) likely undercounts true impact Probable duplicate author record (spelling variant); much work is review/case-series/observational rather than large randomized trials; recent citation impact is minimal.

What would change this assessment: deduplicated (merged-identity) citation totals, evidence of active randomized trial leadership post-2020, or confirmation of affiliation would raise the appraisal; confirmed reliance on guideline-based reviews over original data would lower it. Confidence: moderate — based on one bibliometric source with known author-disambiguation gaps.

 BGPT Author Review

Scientific Quality

A mature clinician-scientist with an h-index of 28 and 2,000+ citations, first-author reviews in recognized gynecology journals, and notable contributions to hydrosalpinx-IVF surgery and MRKHS neovagina outcomes. Strengths are domain authority in adolescent gynecology and collaboration with leading endocrinologists (Chrousos, Mastorakos). Weaknesses: output skewed toward reviews and small clinical series rather than rigorous trials; declining productivity and near-zero citation impact after 2020; identity fragmentation inflates uncertainty about true metrics.

Communication Quality

His reviews (adolescent amenorrhea, menstrual disturbances in puberty, DUB) are widely cited as educational references, implying clear pedagogical writing. However, closed access for much of the work limits reach, and clinical paper abstracts follow conventional, non-novel formats.

Author Novelty

Mostly consolidative reviews and clinical series; novelty comes from the large 111-patient vaginoplasty series and persistence-of-hyperandrogenism findings in postmenopausal PCOS, but no paradigm-shifting work is evident in the record.

Scientific Rigor

High-reference reviews (e.g., HPV immunology with 103 references) and comparative surgical studies suggest reasonable methodological care. Rigor is limited by preponderance of single-center series, observational designs, and small samples (e.g., psychosomatic study), without evidence of multi-center or randomized leadership beyond the 2006 hydrosalpinx trial.